G. Fyfe

3.6k total citations · 1 hit paper
19 papers, 2.7k citations indexed

About

G. Fyfe is a scholar working on Oncology, Virology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, G. Fyfe has authored 19 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 6 papers in Virology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in G. Fyfe's work include HIV Research and Treatment (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Treatment and Pharmacology (5 papers). G. Fyfe is often cited by papers focused on HIV Research and Treatment (6 papers), Colorectal Cancer Treatments and Studies (5 papers) and Cancer Treatment and Pharmacology (5 papers). G. Fyfe collaborates with scholars based in United States, Japan and Australia. G. Fyfe's co-authors include Richard I. Fisher, Mario Sznol, Arthur C. Louie, S A Rosenberg, David Parkinson, Steven A. Rosenberg, Richard T. Davey, Robert Walker, Joseph A. Kovacs and Judith Falloon and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

G. Fyfe

19 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.

1995 1.0k citations G. Fyfe, Richard I. Fisher et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
G. Fyfe United States	15	1.2k	1.0k	839	820	518	19	2.7k
Byron M. Espina United States	29	1.6k 1.4×	1.0k 1.0×	433 0.5×	455 0.6×	105 0.2×	73	3.5k
Amrita Krishnan United States	35	2.8k 2.4×	241 0.2×	721 0.9×	2.2k 2.7×	274 0.5×	198	5.6k
Deborah Jean Lee Wong United States	14	887 0.7×	396 0.4×	408 0.5×	239 0.3×	127 0.2×	53	1.6k
Vallì De Re Italy	37	1.4k 1.1×	403 0.4×	930 1.1×	730 0.9×	64 0.1×	180	4.4k
Roland E. Knoblauch United States	22	1.1k 0.9×	1.3k 1.2×	189 0.2×	738 0.9×	206 0.4×	85	2.2k
Dale L. Bixby United States	27	756 0.6×	122 0.1×	432 0.5×	1.1k 1.4×	365 0.7×	135	3.2k
Janet W. Andersen United States	26	499 0.4×	184 0.2×	166 0.2×	1.2k 1.4×	96 0.2×	47	2.6k
Andre Lopes United Kingdom	23	707 0.6×	350 0.3×	714 0.9×	238 0.3×	137 0.3×	54	2.3k
Jean Gabarre France	31	2.2k 1.9×	330 0.3×	429 0.5×	152 0.2×	104 0.2×	81	3.3k
M Boiocchi Italy	31	1.8k 1.5×	376 0.4×	391 0.5×	660 0.8×	29 0.1×	94	3.3k

Countries citing papers authored by G. Fyfe

Since Specialization

Citations

This map shows the geographic impact of G. Fyfe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Fyfe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Fyfe more than expected).

Fields of papers citing papers by G. Fyfe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Fyfe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Fyfe. The network helps show where G. Fyfe may publish in the future.

Co-authorship network of co-authors of G. Fyfe

This figure shows the co-authorship network connecting the top 25 collaborators of G. Fyfe. A scholar is included among the top collaborators of G. Fyfe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Fyfe. G. Fyfe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

1.

Kaiser, Lee D., Allen S. Melemed, A. Preston, et al.. (2010). Optimizing Collection of Adverse Event Data in Cancer Clinical Trials Supporting Supplemental Indications. Journal of Clinical Oncology. 28(34). 5046–5053. 13 indexed citations

2.

Mass, R., G. Fyfe, J. Hambleton, et al.. (2004). Bevacizumab in combination with 5-FU/leucovorin improves survival in patients with metastatic colorectal cancer: A combined analysis. Journal of Clinical Oncology. 22(14_suppl). 3616–3616. 18 indexed citations

3.

Fyfe, G., Herbert I. Hurwitz, L. Fehrenbacher, et al.. (2004). Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. Journal of Clinical Oncology. 22(14_suppl). 3617–3617. 16 indexed citations

4.

Fyfe, G., H. Hurwitz, Louis Fehrenbacher, et al.. (2004). Bevacizumab plus irinotecan/5-FU/leucovorin for treatment of metastatic colorectal cancer results in survival benefit in all pre-specified patient subgroups. Journal of Clinical Oncology. 22(14_suppl). 3617–3617. 31 indexed citations

5.

Mass, R., G. Fyfe, J. Hambleton, et al.. (2004). Bevacizumab in combination with 5-FU/leucovorin improves survival in patients with metastatic colorectal cancer: A combined analysis. Journal of Clinical Oncology. 22(14_suppl). 3616–3616. 5 indexed citations

6.

Markowitz, Norman, H. Clifford Lane, Louis D. Saravolatz, et al.. (2003). A randomized controlled trial evaluating the efficacy and safety of intermittent 3-, 4-, and 5-day cycles of intravenous recombinant human Interleukin-2 combined with antiretroviral therapy (ART) versus ART alone in HIV-seropositive patients with 100–300 CD4+ t cells. Clinical Immunology. 106(3). 188–196. 11 indexed citations

7.

Prados, Michael, Susan M. Chang, Eric Burton, et al.. (2003). 33 Phase I study of OSI-774 alone or with temozolomide in patients with malignant glioma. European Journal of Cancer Supplements. 1(5). S14–S14. 45 indexed citations

8.

Fyfe, G., R. Mass, Mariela Blum Murphy, & DJ Slamon. (2001). Older (age > 60 years) patients obtain survival benefit from herceptin plus chemotherapy. European Journal of Cancer. 37. S189–S190. 4 indexed citations

9.

Margolin, Kim, Michael Gordon, Eric Holmgren, et al.. (2001). Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination With Chemotherapy in Patients With Advanced Cancer: Pharmacologic and Long-Term Safety Data. Journal of Clinical Oncology. 19(3). 851–856. 299 indexed citations

10.

Fisher, Richard I., Steven A. Rosenberg, & G. Fyfe. (2000). Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.. PubMed. 6 Suppl 1. S55–7. 352 indexed citations

11.

Davey, Richard T., Doreen Chaitt, Jeffrey M. Albert, et al.. (1999). A Randomized Trial of High‐ versus Low‐Dose Subcutaneous Interleukin‐2 Outpatient Therapy for Early Human Immunodeficiency Virus Type 1 Infection. The Journal of Infectious Diseases. 179(4). 849–858. 112 indexed citations

12.

Carr, Andrew, Sean Emery, Andrew R. Lloyd, et al.. (1998). Outpatient Continuous Intravenous Interleukin‐2 or Subcutaneous, Polyethylene Glycol‐Modified Interleukin‐2 in Human Immunodeficiency Virus‐Infected Patients: A Randomized, Controlled, Multicenter Study. The Journal of Infectious Diseases. 178(4). 992–999. 69 indexed citations

13.

Davey, Richard T., Doreen Chaitt, Stephen C. Piscitelli, et al.. (1997). Subcutaneous Administration of Interleukin‐2 in Human Immunodeficiency Virus Type 1—Infected Persons. The Journal of Infectious Diseases. 175(4). 781–789. 139 indexed citations

14.

Fisher, Richard I., et al.. (1997). High-dose aldesleukin in renal cell carcinoma: long-term survival update.. PubMed. 3 Suppl 1. S70–2. 72 indexed citations

15.

Kovacs, Joseph A., Susan Vogel, Jeffrey M. Albert, et al.. (1996). Controlled Trial of Interleukin-2 Infusions in Patients Infected with the Human Immunodeficiency Virus. New England Journal of Medicine. 335(18). 1350–1356. 320 indexed citations

16.

Fyfe, G., Richard I. Fisher, S A Rosenberg, et al.. (1995). Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.. Journal of Clinical Oncology. 13(3). 688–696. 1041 indexed citations breakdown →

17.

Lipman, Brian, et al.. (1995). Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood. 86(9). 3287–3294. 73 indexed citations

18.

Fyfe, G., et al.. (1987). Subpopulations of B lymphocytes in germinal centers.. The Journal of Immunology. 139(7). 2187–2194. 42 indexed citations

19.

Ammann, Arthur J., et al.. (1985). Beh?et syndrome. The Journal of Pediatrics. 107(1). 41–43. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact